Orforglipron FDA Approval Status October 2026

Scope note: This status page tracks the U.S. FDA answer, core trial evidence, and approval timing only. Prescription approval and RUO supply are separate lanes, and Remy Research does not supply Foundayo or prescription GLP-1 medicines.

What Is Orforglipron FDA Approval Status in 2026?

Yes — orforglipron is FDA approved in 2026. Foundayo (orforglipron) received U.S. approval on April 1, 2026 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. As of October 7, 2026, that remains the U.S. label status. Lilly has submitted a type 2 diabetes application to the FDA, and no decision on it has been announced. Outside the U.S., the UK MHRA authorised orforglipron on August 10, 2026 for weight management and type 2 diabetes.

The approval made Foundayo the first non-peptide oral GLP-1 receptor agonist cleared for obesity. FDA said the decision arrived 50 days after filing under the Commissioner’s National Priority Voucher pilot program. For label details and launch context, see the Foundayo FDA approval deep dive.

What Is Orforglipron (Foundayo)?

Orforglipron is Eli Lilly’s once-daily oral non-peptide GLP-1 receptor agonist, now approved for obesity in the United States under the brand name Foundayo. The non-peptide structure is the key differentiator — unlike peptide-based oral GLP-1 drugs such as oral semaglutide, orforglipron does not require fasting before dosing or restrictions on food and water intake after administration. For a detailed comparison of oral GLP-1 compounds, see Oral Obesity Drugs in 2026.

Eli Lilly has already secured the U.S. obesity approval and has submitted orforglipron for type 2 diabetes in the U.S. (Q2 2026 report). The current U.S. status answer now turns less on launch commentary and more on label scope, post-approval evidence, and how the obesity and diabetes programs continue across the broader development plan. For the label and program specifics, see our Foundayo (orforglipron) FDA approval details.

Lilly positions orforglipron as an oral GLP-1 that eliminates the formulation constraints that have historically limited peptide-based oral drugs. This practical advantage is distinct from mechanism of action — orforglipron activates the same GLP-1 receptor as semaglutide, but delivers it in a structurally different oral format.

What Did the ATTAIN-1 Phase 3 Trial Show?

In August 2025, Eli Lilly reported positive Phase 3 obesity data from the ATTAIN-1 trial. The FDA-approved Foundayo label caps maintenance dosing at 17.2 mg, which delivered approximately 12.4% mean weight loss at 72 weeks; the higher 36 mg trial dose produced approximately 14.3%. The FDA approved orforglipron on April 1, 2026 as Foundayo. It is a once-daily small molecule oral glucagon-like peptide-1 receptor agonist designed to mimic the GLP-1 hormone and activate its receptors throughout the body.

The ATTAIN-1 trial also showed improvements in cardiometabolic risk factors alongside weight reduction. Notably, orforglipron can be taken any time of the day without restrictions on food and water intake, unlike oral semaglutide which requires fasting. With the U.S. obesity approval now secured, the remaining near-term watch points are launch execution, the FDA decision on the type 2 diabetes submission, the EU review and other global registrations.

ACHIEVE-3: Orforglipron vs Oral Semaglutide

A pivotal head-to-head clinical trial, ACHIEVE-3, compared orforglipron and oral semaglutide in 1,698 participants with type 2 diabetes over 52 weeks, using four treatment arms: orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, and oral semaglutide 14 mg. Orforglipron delivered superior blood sugar control compared to oral semaglutide, lowering A1C by 2.2% versus 1.4%. Participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss.

Orforglipron showed clinically meaningful improvements from baseline across key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure, and triglycerides. Discontinuation rates due to adverse events were higher for orforglipron (about 9–10%) compared to oral semaglutide (4–5%), mainly due to gastrointestinal symptoms. The most common adverse events included nausea, diarrhea, vomiting, dyspepsia, and decreased appetite. Orforglipron is also being investigated for treating hypertension and obstructive sleep apnea.

The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes. Research suggests tirzepatide may be more effective than orforglipron for both weight loss and blood sugar control. Retatrutide, the triple-receptor agonist, posts among the highest weight-loss figures reported in current obesity trials — see the retatrutide research profile for its mechanism and trial data. The lead investigator for the ACHIEVE-3 trial is based at Texas Southwestern Medical Center.

ATTAIN-MAINTAIN: Maintaining Weight Loss After Injectables

A Phase 3b switch/maintenance trial, ATTAIN-MAINTAIN, was published in Nature Medicine on May 12, 2026. It tested whether patients who stopped an injectable GLP-1 could hold onto their results by switching to oral orforglipron. After discontinuing injectables, orforglipron preserved a mean of approximately 75% of prior weight loss in post-tirzepatide patients and 79% in post-semaglutide patients at 52 weeks, versus 49% and 38% respectively on placebo.

This is the first peer-reviewed evidence that an oral GLP-1 receptor agonist can maintain weight loss after injectable therapy is withdrawn — a key practical question given the documented weight regain seen after stopping injectables. For more on that pattern, see GLP-1 discontinuation and weight regain data.

What Happens Next?

Three developments define the near-term path for orforglipron:

1. U.S. label implementation. The obesity approval is already secured, so the next practical milestone is how the approved label, payer decisions, and prescriber uptake evolve in the United States.

2. Additional label expansion data. The ATTAIN and ACHIEVE programs continue to generate obesity and type 2 diabetes data. Those readouts matter less for the base obesity approval answer now, and more for label expansion, payer positioning, and cross-indication strategy. Detailed ACHIEVE-4 results (September 30, 2026) in 2,749 adults with type 2 diabetes and higher cardiovascular risk showed MACE-4 hazard ratio 0.84 (95% CI 0.59–1.20) versus insulin glargine, meeting the prespecified non-inferiority test.

3. Competitive positioning. The key research question is now how Foundayo stacks up against oral semaglutide and injectable leaders. Its non-peptide format and no-fasting routine are the clearest differentiators. For a direct efficacy comparison, see Retatrutide vs Orforglipron, and for broader pipeline context use the obesity drug approval tracker.

Why Does This Matter Now?

Orforglipron is the first non-peptide oral GLP-1 agonist approved for obesity — a meaningful distinction from the peptide-based Wegovy pill. The development of orforglipron is the result of extensive drug research, including preclinical pharmacology studies and Phase 3 clinical trials, highlighting the scientific innovation behind its creation.

The practical implications are significant. Small-molecule drug design is reshaping the landscape of obesity and diabetes research. Peptide-based oral drugs require specific dosing conditions — empty stomach, small amounts of water, waiting periods before eating — that affect real-world adherence. A non-peptide oral GLP-1 without those restrictions changes the convenience profile and gives researchers a cleaner comparison point for oral obesity therapies.